In humans, impulsivity measured as false alarms in a Go/No-Go task is reportedly decreased by amphetamine and is not affected by oxycodone and delta(9)tetrahydrocannabinol. To model these findings in animals, three rhesus monkeys were trained to perform a foodreinforced Go/No-Go task. In this task, amphetamine was found to decrease false alarms (i.e. responding during No-Go trials), but only at doses that also decreased hits (i.e. responding during Go trials). Morphine generally decreased hits but not false alarms. The cannabinoid receptor agonist CP 55, 940 decreased both false alarms and hits, but only at doses that also decreased the number of trials completed. Additional studies in animals and humans are necessary to delineate the conditions under which amphetamine and other psychoactive drugs affect impulsivity in Go/No-Go tasks. Behavioural Pharmacology 26:481-484
Introduction
Impulsivity is closely linked to drug abuse (De Wit, 2008) . The present study is part of an effort to develop procedures suitable to investigate drug effects on impulsivity in nonhumans. Here, a Go/No-Go procedure was used to examine drug effects on behavioral inhibition. In humans, acute administration of amphetamine decreases several measures of impulsivity, including false alarms, in a Go/No-Go task (De Wit et al., 2002) . In contrast, the opioid oxycodone does not alter measures of impulsivity in humans (Zacny and De Wit, 2009 ). Delta (9)-tetrahydrocannabinol increases some measures of impulsivity (i.e. response inhibition in a stop task) but not others (e.g. Go/No-Go task performance) in humans (McDonald et al., 2003) . To determine whether these findings can be modeled in nonhumans, the present study examined the effects of amphetamine, morphine, and the cannabinoid receptor agonist CP 55, 940 on Go/ No-Go task performance in rhesus monkeys.
Method Subjects
One male (KI) and two female (HE, JA) adult rhesus monkeys were maintained at a constant weight by administering food pellets during sessions and primate chow and fruit in the home cage (with free access to water), in accordance with local Institutional Animal Care and Use Committee and National Institutes of Health guidelines. For further details, see Bai et al. (2011) .
Apparatus
During the sessions, the monkeys were seated in chairs placed in operant chambers equipped with two levers, two lights, and a food pellet receptacle, controlled by MED-PC software. For further details, see Bai et al. (2011) .
Procedure
During the daily sessions, which began with a 15 min time-out in the operant chamber, the monkeys were trained to lever press for food in a self-paced discrete trial Go/No-Go procedure. The trial began by illumination of the light above one lever. A response on that lever extinguished that light and illuminated the other light that flashed for a maximum of 0.8 s at 15 Hz (Go signal) or slower (No-Go signal; KI: 10 Hz; HE, JA: 7.5 Hz). Correct responses (i.e. a response on the second lever during a Go trial and not responding on the second lever during the 0.8 s No-Go trial) extinguished the second light, delivered a food pellet, and started a 5 s intertrial interval. Incorrect responses (i.e. not responding during a Go trial, responding during a No-Go trial) ended the trial without delivering a food pellet and initiated a 10 s time-out before the 5 s intertrial interval started. The session ended after 100 Go trials and 100 No-Go trials (in a random order, but with at most four consecutive trials of the same type) or after 45 min, whichever occurred first. A response on the second lever was designated a hit during Go trials and a false alarm during No-Go trials; training continued until the percentages of hits and false alarms attained stable (as defined by Schoenfeld et al., 1956) high and low levels, respectively. Animals were testable if both hits and false alarms differed by less than 10% between two consecutive saline control sessions. All doses of each drug were tested first in an ascending order and then in a random order. Amphetamine tests were completed before morphine tests began, and CP 55, 940 tests were conducted last.
Drugs
Morphine sulfate (Research Technology Branch, NIDA, Rockville, Maryland, USA) and D-amphetamine sulfate (Sigma-Aldrich Co., St. Louis, Missouri, USA) were dissolved in sterile water; CP 55,940 (Sigma-Aldrich Co.) was dissolved in a 1 : 1 : 18 mixture of absolute ethanol, emulphor-620, and 0.9% saline. All drugs were injected subcutaneously (0.2-1.5 ml) immediately before the sessions, except CP 55, 940, which was injected 45 min before the sessions. Doses were expressed as the weight of the salt.
Data analysis
For each drug test, the proportions of hits and false alarms were used to calculate the sensitivity index (SI) and the response bias index (RI; see Koek and Slangen, 1984) , and frequency distributions yielded modal and mean response latencies. Deviations of the mean from the mode have been used to examine the effects of amphetamine on long reaction times that are thought to constitute lapses of attention (see Acheson and De Wit, 2008; De Wit, 2008) . Test results were considered drug effects if a dose produced, on both tests, results outside the range observed during the saline sessions conducted 24 h before each test.
Results
At the highest dose tested, amphetamine decreased false alarms in KI and JA but increased false alarms in HE, and decreased hits in all three monkeys (Fig. 1, left panels) . Morphine decreased hits in all three monkeys, increased false alarms in KI, and decreased false alarms in JA (middle panels). CP 55, 940 decreased both hits and false alarms, but only at doses that decreased the number of trials completed. The combined effects on hits and false alarms of each of the three drugs decreased SI, indicating decreased sensitivity, and yielded RI values lower than 0, indicating an increased bias not to respond (Fig. 2) . Under vehicle control conditions, the means of the observing response latencies were generally higher than their modes (Table 1) . Amphetamine increased this difference, as did morphine and CP 55, 940. Amphetamine increased the mean Go response latency but not its mode at the higher dose tested in HE and JA monkeys, whereas morphine and CP 55, 940 did not consistently alter Go response latencies (data not shown).
Discussion
In humans, amphetamine decreased false alarms without having significant effects on performance during Go trials, suggesting decreased impulsivity (De Wit et al., 2002) . In a reaction time task in humans, amphetamine decreased the reaction time mean more than the mode, indicating a decrease in the long reaction times thought to constitute lapses of attention (Acheson and De Wit, 2008) . Similar evidence of amphetamine decreasing impulsivity and decreasing lapses of attention was not obtained in the present study in rhesus monkeys. Instead, amphetamine affected false alarms only at doses that also affected responding during Go trials (i.e. hits), reflecting a general bias toward not responding, and amphetamine increased reaction times. The current results are consistent with the findings that amphetamine and methamphetamine decrease responding of mice in Go/No-Go tasks, whereas they have no effects specific to response inhibition during No-Go trials (Loos et al., 2010; Moschak et al., 2012) . In these latter studies, trials were not initiated by an observing response, like in the aforementioned study in humans (De Wit et al., 2002) , but unlike the present study. Thus, a stimulant-induced general reduction in responding does not appear to be specific to the 'self-paced' Go/No-Go task used here.
The present study failed to find consistent effects of morphine on false alarms. These data are consistent with those from human participants, according to which oxycodone and delta(9)-tetrahydrocannabinol did not significantly affect Go/No-Go task performance (McDonald et al., 2003; Zacny and De Wit, 2009 ). Unlike the studies in humans, morphine decreased responding by rhesus monkeys primarily during Go trials in the present experiments, and the cannabinoid agonist CP 55, 940 decreased responding during Go and No-Go trials at doses that decreased the number of trials completed. This could be because of procedural differences, as responding during Go trials is generally very accurate in human Go/No-Go studies (e.g. McDonald et al., 2003; Zacny and De Wit, 2009) . In contrast, the percentage of correct responses during Go trials ('hits') in the present studies varied between 70 and 100%. Overall, the present data strongly suggest that additional studies in animals and humans are necessary to delineate conditions under which amphetamine and other psychoactive drugs selectively affect false alarms in Go/No-Go tasks. Each dose was tested twice, except where indicated by 'nd'. Values in bold are above the range of control latencies indicated under 'vehicle', and underlined values are below the range of vehicle control latencies.
